• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.

作者信息

Mirmosayyeb Omid, Shaygannejad Vahid, Barzegar Mahdi, Nehzat Nasim, Ghajarzadeh Mahsa

机构信息

Department of Neurology, School of medicine, Isfahan University of medical sciences, Isfahan, Iran; Isfahan Neurosciences Research Center, Isfahan University of medical sciences, Isfahan, Iran; Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.

Department of Neurology, School of medicine, Isfahan University of medical sciences, Isfahan, Iran; Isfahan Neurosciences Research Center, Isfahan University of medical sciences, Isfahan, Iran.

出版信息

Autoimmun Rev. 2021 Feb;20(2):102727. doi: 10.1016/j.autrev.2020.102727. Epub 2020 Dec 17.

DOI:10.1016/j.autrev.2020.102727
PMID:33340771
Abstract
摘要

相似文献

1
Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.利妥昔单抗治疗视神经脊髓炎谱系障碍（NMOSD）患者的疗效和安全性：一项系统评价和荟萃分析。
Autoimmun Rev. 2021 Feb;20(2):102727. doi: 10.1016/j.autrev.2020.102727. Epub 2020 Dec 17.
2
Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.利妥昔单抗治疗视神经脊髓炎谱系障碍的疗效：一项更新的系统评价和荟萃分析。
Mult Scler Relat Disord. 2021 May;50:102843. doi: 10.1016/j.msard.2021.102843. Epub 2021 Feb 13.
3
A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.20 例视神经脊髓炎谱系疾病患者接受利妥昔单抗治疗的长期随访。
Mult Scler Relat Disord. 2020 May;40:101933. doi: 10.1016/j.msard.2020.101933. Epub 2020 Jan 5.
4
Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.视神经脊髓炎谱系疾病患者使用利妥昔单抗的长期耐受性、安全性和疗效：一项前瞻性研究。
J Neurol. 2019 Mar;266(3):642-650. doi: 10.1007/s00415-019-09180-9. Epub 2019 Jan 11.
5
Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.利妥昔单抗诱导水通道蛋白 4 免疫球蛋白 G 阳性视神经脊髓炎谱系疾病患者发生间质性肺病。
Mult Scler Relat Disord. 2018 Feb;20:192-193. doi: 10.1016/j.msard.2018.01.006. Epub 2018 Mar 20.
6
Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.利妥昔单抗治疗视神经脊髓炎谱系疾病的疗效和安全性：系统评价和荟萃分析。
JAMA Neurol. 2016 Nov 1;73(11):1342-1348. doi: 10.1001/jamaneurol.2016.1637.
7
Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.视神经脊髓炎谱系疾病治疗的进展。
Neurol Clin. 2021 Feb;39(1):35-49. doi: 10.1016/j.ncl.2020.09.003. Epub 2020 Nov 7.
8
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.利妥昔单抗治疗视神经脊髓炎谱系疾病的安全性和有效性（RIN-1 研究）：一项多中心、随机、双盲、安慰剂对照试验。
Lancet Neurol. 2020 Apr;19(4):298-306. doi: 10.1016/S1474-4422(20)30066-1. Epub 2020 Mar 18.
9
Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.针对视神经脊髓炎谱系疾病的个体化 B 细胞靶向治疗。
Neurochem Int. 2019 Nov;130:104347. doi: 10.1016/j.neuint.2018.11.022. Epub 2018 Dec 1.
10
Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.治疗视神经脊髓炎以改变成年患者病程的有效性。文献系统评价。
Mult Scler Relat Disord. 2021 May;50:102869. doi: 10.1016/j.msard.2021.102869. Epub 2021 Feb 25.

引用本文的文献

1
Pregnancy Outcomes in Women with Multiple Sclerosis Who Had Exposure to Rituximab: a Systematic Review and Meta-Analysis.接触利妥昔单抗的多发性硬化症女性的妊娠结局：一项系统评价和荟萃分析。
Maedica (Bucur). 2025 Mar;20(1):106-111. doi: 10.26574/maedica.2025.20.1.106.
2
Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.视神经脊髓炎谱系疾病（NMOSD）中使用靶向B细胞的单克隆抗体治疗期间的复发情况。
J Neurol. 2025 May 18;272(6):406. doi: 10.1007/s00415-025-13118-9.
3
Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.
视神经脊髓炎谱系障碍患者停用利妥昔单抗后的复发风险：一项多中心回顾性队列研究
J Neurol. 2025 May 10;272(6):387. doi: 10.1007/s00415-025-13125-w.
4
A meaningful exploration of ofatumumab in refractory NMOSD: a case report.奥法妥木单抗治疗难治性 NMOSD 的意义探索：一例报告。
Front Immunol. 2023 Jun 28;14:1208017. doi: 10.3389/fimmu.2023.1208017. eCollection 2023.
5
Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis.视神经脊髓炎谱系障碍患者单克隆抗体治疗的疗效与安全性：一项系统评价与网状Meta分析
Front Neurol. 2023 Apr 4;14:1166490. doi: 10.3389/fneur.2023.1166490. eCollection 2023.
6
A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders.一项关于利妥昔单抗治疗视神经脊髓炎谱系疾病的疗效和安全性的荟萃分析。
Medicine (Baltimore). 2022 Sep 9;101(36):e30347. doi: 10.1097/MD.0000000000030347.